.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BX05_Pramlintide.Pramlintide .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BX05_Pramlintide.Pramlintide| name: | Pramlintide | |
| ATC code: | A10BX05 | route: | subcutaneous |
| compartments: | 2 | |
| dosage: | 120 | mg |
| volume of distribution: | 0.25 | L |
| clearance: | 1.2 | L/h/kg |
| other parameters in model implementation | ||
Pramlintide is a synthetic analogue of human amylin, a peptide hormone co-secreted with insulin by pancreatic beta cells. It is used as an adjunct to insulin therapy for the treatment of type 1 and type 2 diabetes mellitus to control postprandial blood glucose levels. Pramlintide is currently approved and marketed for clinical use.
Pharmacokinetic parameters in healthy volunteers and diabetic patients; data typically derived from subcutaneous administration.
Furió-Novejarque, C, et al., & Bondia, J (2024). A model of subcutaneous pramlintide pharmacokinetics and its effect on gastric emptying: Proof-of-concept based on populational data. Computer methods and programs in biomedicine 244 107968–None. DOI:10.1016/j.cmpb.2023.107968 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38064957